Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-26 00:00:00 ET · period of report 2025-02-24 · accession 0000875320-25-000103 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-26 | 2025-02-24 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $483.28 | -828 | 9,970 | -8% | -$400.2K | |
| 2025-02-26 | 2025-02-25 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $480.95 | -884 | 9,086 | -9% | -$425.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-24 | F | D | 828 | $483.28 | 9,970 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-25 | S | D | 884 | $480.95 | 9,086 | D | — | — |